Doctor critiques three hyped medical advances and their real-world limits

Dr. Mason Pimsler warns that the FDA-approved Shield Blood Test, though praised for avoiding colonoscopy prep, only detects about 55%-65% of stage-1 colorectal cancers and fails to identify most precancerous lesions. He notes that a negative result may still leave patients with undetected polyps that could later develop into cancer. At-home Alzheimer’s biomarker kits, while convenient, can produce misleading positive results and trigger undue stress, particularly for patients with anxiety disorders, and they do not currently enable prevention or treatment.

Regarding GeneSight, a cheek-swab test that predicts responses to psychiatric drugs, Pimsler calls it ineffective, saying it cannot substitute the traditional trial-and-error process or replace comprehensive clinical assessment. He also references FDA cautions about the limits of such pharmacogenomic tests. Overall, the doctor urges clinicians and patients to view these innovations with realistic expectations rather than as miracle solutions.